Kincell Bio

Kincell Bio is a technology-forward contract development and manufacturing organisation (CDMO) specialising in cell therapies.

Company Overview

Established in 2023 as a spin-out from Inceptor Bio, Kincell Bio is headquartered in Gainesville, Florida, with an additional facility in Research Triangle Park, North Carolina.

The company focuses on streamlining Chemistry, Manufacturing, and Controls (CMC) development, offering expertise in analytical and process development, as well as Good Manufacturing Practice (GMP) manufacturing, testing, and release. Kincell Bio is dedicated to supporting innovative companies developing immune cell therapies, including autologous and allogeneic CAR-T, CAR-NK, and CAR-M programmes.

Key Products and Services

• Analytical Development: Kincell Bio provides expert analytical testing to ensure the quality, consistency, and potency of cell therapy products.
• Process Development: The company offers phase-appropriate development strategies to ensure right-first-time performance in manufacturing processes.
• cGMP Manufacturing: Kincell Bio specialises in the efficient manufacturing of early-phase cell therapy products, adhering to the highest quality standards.

Recent Developments

In April 2024, Kincell Bio expanded its capabilities by acquiring a 32,800-square-foot manufacturing facility in Research Triangle Park, North Carolina, from Imugene Limited. This acquisition enables Kincell to support mid- to late-stage clinical studies and underscores its commitment to advancing cell therapy manufacturing.

Kincell Bio's mission is to accelerate the development and delivery of life-saving cell therapies by providing comprehensive and tailored CDMO services to its clients.